Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva gets taste of its own antidepressant

Executive Summary

At least seven of the 16 firms with approvals for generic sertraline hydrochloride decide to launch their versions of Pfizer's antidepressant Zoloft after Teva's 180-day exclusivity expired Feb. 6. In January, Teva filed patent infringement lawsuits against multiple generic manufacturers, claiming the generics violate patents which relate to methods for manufacturing. According to IMS data, the generic substitution rate for Zoloft was 89 percent as of Dec. 15, with Teva controlling 45.4 percent of the generic share. The remaining portion went to Greenstone, Pfizer's authorized generics business...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS048033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel